Login to Your Account



Clinic Roundup


Tuesday, November 15, 2011
• Anavex Life Sciences Corp., of Hoboken, N.J., completed a Phase I single ascending dose trial of Anavex 2-73, the first of a new class of oral drugs being developed to treat Alzheimer's through disease modification rather than focusing on symptomatic improvement. Anavex 2-73 was well tolerated below the 55 mg to 60 mg dose with only mild adverse events in some volunteers. The company plans to begin a multiple ascending dose trial immediately.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription